242 related articles for article (PubMed ID: 33687124)
1. Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features and Acts as an Unfavorable Prognostic Biomarker in Glioma.
Zeng F; Li G; Liu X; Zhang K; Huang H; Jiang T; Zhang Y
Oncologist; 2021 Aug; 26(8):e1460-e1469. PubMed ID: 33687124
[TBL] [Abstract][Full Text] [Related]
2. Novel prognostic biomarker TBC1D1 is associated with immunotherapy resistance in gliomas.
Song D; Yang Q; Li L; Wei Y; Zhang C; Du H; Ren G; Li H
Front Immunol; 2024; 15():1372113. PubMed ID: 38529286
[TBL] [Abstract][Full Text] [Related]
3. Gene Association Study of the Urokinase Plasminogen Activator and Its Receptor Gene in Alzheimer's Disease.
Cetinsoy O; Anyanwu I; Krishnanand H; Natarajan G; Ramachandran N; Thomas A; Brookes KJ
J Alzheimers Dis; 2024; 99(1):241-250. PubMed ID: 38669542
[TBL] [Abstract][Full Text] [Related]
4. Functional characterization of TSPAN7 as a novel indicator for immunotherapy in glioma.
Chen L; Liu H; Li Y; Lin X; Xia S; Wanggou S; Li X
Front Immunol; 2023; 14():1105489. PubMed ID: 36845098
[TBL] [Abstract][Full Text] [Related]
5. Prognostic biomarker HIF1α and its correlation with immune infiltration in gliomas.
Ding Z; Zhang J; Li L; Wang C; Mei J
Oncol Lett; 2024 May; 27(5):193. PubMed ID: 38495835
[TBL] [Abstract][Full Text] [Related]
6. Glioma: bridging the tumor microenvironment, patient immune profiles and novel personalized immunotherapy.
Mishchenko TA; Turubanova VD; Gorshkova EN; Krysko O; Vedunova MV; Krysko DV
Front Immunol; 2023; 14():1299064. PubMed ID: 38274827
[TBL] [Abstract][Full Text] [Related]
7. Revealing the role of SPP1
Tang W; Lo CWS; Ma W; Chu ATW; Tong AHY; Chung BHY
Cell Biosci; 2024 Mar; 14(1):37. PubMed ID: 38515213
[TBL] [Abstract][Full Text] [Related]
8. Identification of CREB5 as a prognostic and immunotherapeutic biomarker in glioma through multi-omics pan-cancer analysis.
Wu Z; Wang X; Wu H; Du S; Wang Z; Xie S; Zhang R; Chen G; Chen H
Comput Biol Med; 2024 May; 173():108307. PubMed ID: 38547657
[TBL] [Abstract][Full Text] [Related]
9. Basic Transcription Factor 3 Like 4 Enhances Malignant Phenotypes through Modulating Tumor Cell Function and Immune Microenvironment in Glioma.
Lu B; Lu T; Shi J; Sun P; Zhang X; Yang L; Wang Z; Huang J
Am J Pathol; 2024 May; 194(5):772-784. PubMed ID: 38320629
[TBL] [Abstract][Full Text] [Related]
10. TRIM56: a promising prognostic immune biomarker for glioma revealed by pan-cancer and single-cell analysis.
Wang B; Wang Z; Li Y; Shang Z; Liu Z; Fan H; Zhan R; Xin T
Front Immunol; 2024; 15():1327898. PubMed ID: 38348047
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value and drug sensitivity of F‑box and leucine‑rich repeat protein 6 in glioma.
Lin Q; Zhu J; Zhu W; Zhu H; Li M; Zhao J; Jia S; Nie S
Oncol Lett; 2024 Jul; 28(1):320. PubMed ID: 38807668
[TBL] [Abstract][Full Text] [Related]
12. CHRNA9 as a New Prognostic Marker and Potential Therapeutic Target in Glioma.
Ma X; Geng R; Zhao Y; Xu W; Li Y; Jiang Y; Liu Y; Zhao L; Li Y
J Cancer; 2024; 15(8):2095-2109. PubMed ID: 38495483
[No Abstract] [Full Text] [Related]
13. The role of ST3GAL4 in glioma malignancy, macrophage infiltration, and prognostic outcomes.
Zheng W; Zhang H; Huo Y; Zhang L; Sa L; Shan L; Wang T
Heliyon; 2024 May; 10(9):e29829. PubMed ID: 38707472
[TBL] [Abstract][Full Text] [Related]
14. Endothelial-specific Enhancer as a Cis Element of PLAUR Regulation by TNF-alpha, IL-1beta, and VEGF.
Penkov D; Beloglazova I; Parfyonova Y
Curr Pharm Des; 2024 May; ():. PubMed ID: 38715331
[TBL] [Abstract][Full Text] [Related]
15. Association of TNFRSF19 with a TNF family-based prognostic model and subtypes in gliomas using machine learning.
Guo Y; Zhou Q; Wei M; Fan J; Huang H
Heliyon; 2024 Apr; 10(7):e28445. PubMed ID: 38560169
[TBL] [Abstract][Full Text] [Related]
16. PTPN7 mediates macrophage-polarization and determines immunotherapy in gliomas: A single-cell sequencing analysis.
Ji X; Cheng J; Su J; Wen R; Zhang Q; Liu G; Peng Y; Mao J
Environ Toxicol; 2024 Apr; ():. PubMed ID: 38581214
[TBL] [Abstract][Full Text] [Related]
17. Exploring the impact of ITGB2 on glioma progression and treatment: Insights from non-apoptotic cell death and immunotherapy.
Zhuang J; Miao C; Liu C; Zeng B; Hu L; Peng J; Xia Y; Chen Z
Environ Toxicol; 2024 Mar; ():. PubMed ID: 38488682
[TBL] [Abstract][Full Text] [Related]
18. Soluble urokinase plasminogen activator receptor is associated with kidney disease and its progression in sickle cell anemia.
Zahr RS; Rashkin SR; Ruiz MA; Elsherif L; Ren G; Salas G; Ataga KI; Gordeuk VR; Lebensburger J; Zhang X; Saraf SL
Haematologica; 2024 May; ():. PubMed ID: 38695132
[TBL] [Abstract][Full Text] [Related]
19. Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia.
Wang D; Wang N; Li X; Chen X; Shen B; Zhu D; Zhu L; Xu Y; Yu Y; Shu Y
Gastric Cancer; 2021 Jul; 24(4):823-834. PubMed ID: 33687617
[TBL] [Abstract][Full Text] [Related]
20. An integrated model of N6-methyladenosine regulators to predict tumor aggressiveness and immune evasion in pancreatic cancer.
Zhou Z; Zhang J; Xu C; Yang J; Zhang Y; Liu M; Shi X; Li X; Zhan H; Chen W; McNally LR; Fung KM; Luo W; Houchen CW; He Y; Zhang C; Li M
EBioMedicine; 2021 Mar; 65():103271. PubMed ID: 33714027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
